Claims
- 1. A substantially purified polypeptide comprising the amino acid sequence of SEQ ID NO:2 or variants or fragments thereof.
- 2. An isolated and purified polynucleotide encoding the polypeptide of claim 1.
- 3. An isolated and purified polynucleotide that exhibits at least 80% sequence identity to the polynucleotide of SEQ ID NO:1.
- 4. An isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide of claim 2.
- 5. An isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide of claim 3.
- 6. An isolated and purified polynucleotide which is complementary to the polynucleotide of claim 2.
- 7. An isolated and purified polynucleotide which is complementary to the polynucleotide of claim 3.
- 8. An expression vector comprising the polynucleotide of claim 2 or fragments thereof.
- 9. The expression vector of claim 8 further comprising a nucleotide sequence encoding a β subunit of prolyl 4-hydroxylase.
- 10. A host cell comprising the polynucleotide of claim 2.
- 11. A host cell of claim 10, wherein the host cell further comprises one or more polynucleotide sequences encoding a beta subunit of prolyl 4-hydroxylase.
- 12. The host cell of claim 10, wherein the host cell further comprises one or more nucleotide sequences encoding one or more collagen molecules.
- 13. The host cell of claim 10, wherein the cell is a eukaryotic cell.
- 14. The host cell or claim 10, wherein the cell is a prokaryotic cell.
- 15. The host cell of claim 10, wherein the host cell is selected from the group consisting of insect cells, yeast cells, bacterial cells, plant cells, or mammalian cells.
- 16. A method for producing a polypeptide, the method comprising:
(a) culturing the host cell of claim 10 under conditions suitable for expression of the polypeptide; and (b) isolating the polypeptide.
- 17. A method for producing a prolyl 4-hydroxylase tetramer, the method comprising:
(a) culturing the host cell of claim 11 under conditions suitable for formation of the prolyl 4-hydroxylase tetramer; and (b) recovering the prolyl 4-hydroxylase tetramer.
- 18. A method for detecting a polynucleotide in a sample, the method comprising:
(a) hybridizing the polynucleotide of claim 2 to at least one nucleic acid in a sample, thereby forming a hybridization complex; and (b) detecting the hybridization complex, wherein the presence of the hybridization complex is indicative of the presence of the polynucleotide in the sample.
- 19. A pharmaceutical composition comprising the polypeptide of claim 1 and a suitable pharmaceutical carrier.
- 20. A pharmaceutical composition comprising the polynucleotide of claim 2 and a suitable pharmaceutical carrier.
- 21. A purified antibody which specifically binds to the polypeptide of claim 1.
- 22. A purified agonist of the polypeptide of claim 1.
- 23. A purified antagonist of the polypeptide of claim 1.
- 24. A method for treating or preventing a disorder associated with decreased expression or activity of the alpha(III) subunit of prolyl 4-hydroxylase, the method comprising administering to a subject in need an effective amount of the pharmaceutical composition of claim 19.
- 25. A method for treating or preventing a disorder associated with decreased expression or activity of the alpha(III) subunit of prolyl 4-hydroxylase, the method comprising administering to a subject in need an effective amount of the pharmaceutical composition of claim 20.
- 26. A method for treating or preventing a disorder associated with increased expression or activity of the alpha(III) subunit of prolyl 4-hydroxylase, the method comprising administering to a subject in need an effective amount of the antagonist of claim 23.
- 27. A method of aiding in the diagnosis of a condition associated with altered expression of an alpha(III) subunit of prolyl 4-hydroxylase, comprising (a) detecting the expression of an alpha(III) subunit gene in a test sample;
and (b) comparing result of step (a) to expression levels of the alpha(III) subunit gene in a control cell, wherein altered of the alpha(III)subunit gene in the test sample is indicative of the condition.
- 28. A solid phase support comprising the polynucleotide of claim 2.
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application is related to provisional patent application Ser. No. 60/189,373, filed Mar. 15, 2000, from which priority is claimed under 35 USC §119(e)(1) and which is incorporated herein by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60189373 |
Mar 2000 |
US |